Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice

Oncotarget

Volumn 7, Issue 45, 2016, Pages 74107-74119

  Pyo, Kyoung Ho ^a,d   Lee, You Won ^a   Lim, Sun Min ^b   Shin, Eun Hee ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b CHA University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Antitumor; Profilin; Toll like receptor; Toxoplasma gondii; Vaccine

Indexed keywords

AUTOLOGOUS WHOLE TUMOR CELL VACCINE; B7 ANTIGEN; CD86 ANTIGEN; CHEMOKINE; CXCL1 CHEMOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIGEL; MOLECULAR SCAFFOLD; MONOCYTE CHEMOTACTIC PROTEIN 5; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN; RANTES; RECOMBINANT PROTEIN; TOXOPLASMA GONDII PROFILIN LIKE PROTEIN; TUMOR VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; PROFILIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CANCER IMMUNIZATION; CANCER SURVIVAL; CARCINOMA CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MOTILITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN BLOOD LEVEL; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; TUMOR CELL; TUMOR VOLUME; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; COLON TUMOR; HUMAN; IMMUNOLOGY; SIGNAL TRANSDUCTION; TOXOPLASMA; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; PROFILINS; SIGNAL TRANSDUCTION; TOXOPLASMA;

EID: 84995785857     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12316     Document Type: Article

References (44)

1. Weiss EM, Wunderlich R, Ebel N, Rubner Y, Schlucker E, Meyer-Pittroff R, Ott OJ, Fietkau R, Gaipl US, Frey B. Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Frontiers in oncology. 2012; 2:132.
2. Sharma RK, Schabowsky RH, Srivastava AK, Elpek KG, Madireddi S, Zhao H, Zhong Z, Miller RW, Macleod KJ, Yolcu ES, Shirwan H. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer research. 2010; 70:3945-3954.
3. Lladser A, Mougiakakos D, Tufvesson H, Ligtenberg MA, Quest AF, Kiessling R, Ljungberg K. DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Molecular therapy: the journal of the American Society of Gene Therapy. 2011; 19:594-601.
4. Cicchelero L, de Rooster H, Sanders NN. Various ways to improve whole cancer cell vaccines. Expert review of vaccines. 2014; 13:721-735.
5. Gonzalez FE, Gleisner A, Falcon-Beas F, Osorio F, Lopez MN, Salazar-Onfray F. Tumor cell lysates as immunogenic sources for cancer vaccine design. Human vaccines & immunotherapeutics. 2014; 10:3261-3269.
6. Komai T, Okamura T, Yamamoto K, Fujio K. The effects of TGF-betas on immune responses. Nihon Rinsho Men'eki Gakkai kaishi. 2016; 39:51-58.
7. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, Kronenberg M. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nature immunology. 2009; 10:1178-1184.
8. Seledtsov VI, Goncharov AG, Seledtsova GV. Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Human vaccines & immunotherapeutics. 2015; 11:851-869.
9. Krummen M, Balkow S, Shen L, Heinz S, Loquai C, Probst HC, Grabbe S. Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy. Journal of leukocyte biology. 2010; 88:189-199.
10. Abdul-Cader MS, Amarasinghe A, Abdul-Careem MF. Activation of toll-like receptor signaling pathways leading to nitric oxide-mediated antiviral responses. Archives of virology. 2016.
11. Plattner F, Yarovinsky F, Romero S, Didry D, Carlier MF, Sher A, Soldati-Favre D. Toxoplasma profilin is essential for host cell invasion and TLR11-dependent induction of an interleukin-12 response. Cell Host Microbe. 2008; 3:77-87.
12. Salazar Gonzalez RM, Shehata H, O'Connell MJ, Yang Y, Moreno-Fernandez ME, Chougnet CA, Aliberti J. Toxoplasma gondii-derived profilin triggers human toll-like receptor 5-dependent cytokine production. J Innate Immun. 2014; 6:685-694.
13. Koblansky AA, Jankovic D, Oh H, Hieny S, Sungnak W, Mathur R, Hayden MS, Akira S, Sher A, Ghosh S. Recognition of profilin by Toll-like receptor 12 is critical for host resistance to Toxoplasma gondii. Immunity. 2013; 38:119-130.
14. Toussi DN, Massari P. Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands. Vaccines (Basel). 2014; 2:323-353.
15. Adams M, Navabi H, Jasani B, Man S, Fiander A, Evans AS, Donninger C, Mason M. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically nontoxic double stranded RNA analogue poly [I]:poly [C(12) U] (Ampligen R). Vaccine. 2003; 21:787-790.
16. Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K, Cloughesy T, Lamborn KR, Salazar AM, Prados MD. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol. 2009; 91:175-182.
17. Krown SE, Kerr D, Stewart WE, 2nd, Field AK, Oettgen HF. Phase I trials of poly(I, C) complexes in advanced cancer. J Biol Response Mod. 1985; 4:640-649.
18. Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED, Dong H. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol. 2009; 183:3634-3641.
19. Feyerabend S, Stevanovic S, Gouttefangeas C, Wernet D, Hennenlotter J, Bedke J, Dietz K, Pascolo S, Kuczyk M, Rammensee HG, Stenzl A. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate. 2009; 69:917-927.
20. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother. 2008; 31:520-527.
21. Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol. 2013; 31:2413-2420.
22. Millward M, Underhill C, Lobb S, McBurnie J, Meech SJ, Gomez-Navarro J, Marshall MA, Huang B, Mather CB. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. Br J Cancer. 2013; 108:1998-2004.
23. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrandiz C, Garcia Diez A, Tebbs V, McRae S. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005; 152:939-947.
24. Smorlesi A, Papalini F, Orlando F, Donnini A, Re F, Provinciali M. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Ther. 2005; 12:1324-1332.
25. Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W, Walden P, Zippelius A, Conzett KB, Senti G, Voelter V, Cerottini JP, Guggisberg D, Willers J, Geldhof C, Romero P, et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother. 2010; 33:848-858.
26. Jones RM, Sloane VM, Wu H, Luo L, Kumar A, Kumar MV, Gewirtz AT, Neish AS. Flagellin administration protects gut mucosal tissue from irradiation-induced apoptosis via MKP-7 activity. Gut. 2011; 60:648-657.
27. Nguyen CT, Hong SH, Sin JI, Vu HV, Jeong K, Cho KO, Uematsu S, Akira S, Lee SE, Rhee JH. Flagellin enhances tumor-specific CD8(+) T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model. Vaccine. 2013; 31:3879-3887.
28. Gazzinelli RT, Wysocka M, Hayashi S, Denkers EY, Hieny S, Caspar P, Trinchieri G, Sher A. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii. J Immunol. 1994; 153:2533-2543.
29. Pyo KH, Jung BK, Chai JY, Shin EH. Suppressed CD31 expression in sarcoma-180 tumors after injection with Toxoplasma gondii lysate antigen in BALB/c mice. Korean J Parasitol. 2010; 48:171-174.
30. Pyo KH, Jung BK, Xin CF, Lee YW, Chai JY, Shin EH. Prominent IL-12 production and tumor reduction in athymic nude mice after Toxoplasma gondii lysate antigen treatment. Korean J Parasitol. 2014; 52:605-612.
31. Halonen SK, Weiss LM. Toxoplasmosis. Handb Clin Neurol. 2013; 114:125-145.
32. Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard RB. Helper roles of NK, CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunologic research. 2006; 36:137-146.
33. Yarovinsky F. Innate immunity to Toxoplasma gondii infection. Nature reviews Immunology. 2014; 14:109-121.
34. Rankin EB, Yu D, Jiang J, Shen H, Pearce EJ, Goldschmidt MH, Levy DE, Golovkina TV, Hunter CA, Thomas-Tikhonenko A. An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth. Cancer Biol Ther. 2003; 2:687-693.
35. Engel MA, Neurath MF. Anticancer properties of the IL-12 family-focus on colorectal cancer. Curr Med Chem. 2010; 17:3303-3308.
36. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009; 22:240-273, Table of Contents.
37. Miyaji EN, Carvalho E, Oliveira ML, Raw I, Ho PL. Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants. Braz J Med Biol Res. 2011; 44:500-513.
38. Legitimo A, Consolini R, Failli A, Orsini G, Spisni R. Dendritic cell defects in the colorectal cancer. Human vaccines & immunotherapeutics. 2014; 10:3224-3235.
39. Araki-Sasaki K, Tanaka T, Ebisuno Y, Kanda H, Umemoto E, Hayashi K, Miyasaka M. Dynamic expression of chemokines and the infiltration of inflammatory cells in the HSV-infected cornea and its associated tissues. Ocular immunology and inflammation. 2006; 14:257-266.
40. Li J, Ley K. Lymphocyte migration into atherosclerotic plaque. Arteriosclerosis, thrombosis, and vascular biology. 2015; 35:40-49.
41. Robertson MJ. Role of chemokines in the biology of natural killer cells. Journal of leukocyte biology. 2002; 71:173-183.
42. de Jong EC, Smits HH, Kapsenberg ML. Dendritic cell-mediated T cell polarization. Springer seminars in immunopathology. 2005; 26:289-307.
43. Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 2000; 11:321-333.
44. Moon JH, Pyo KH, Jung BK, Chun HS, Chai JY, Shin EH. Resistance to Toxoplasma gondii infection in mice treated with silk protein by enhanced immune responses. The Korean journal of parasitology. 2011; 49:303-308.